Tianeptine
- Generic Name
- Tianeptine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClN2O4S
- CAS Number
- 72797-41-2
- Unique Ingredient Identifier
- 0T493YFU8O
- Background
Tianeptine is a drug used primarily in the treatment of major depressive disorder and has been studied in the treatment of irritable bowel syndrome (IBS) . Structurally, it is classified as a tricyclic antidepressant (TCA), however, it possesses different pharmacological properties than typical tricyclic antidepressants .
Tianeptine was discovered and patented by The French Society of Medical Research in the 1960s . Currently, tianeptine is approved in France and manufactured and marketed by Laboratories Servier SA; it is also marketed in several other European countries under the trade name “Coaxil” as well as in Asia (including Singapore) and Latin America as “Stablon” and “Tatinol” but it is not available in Australia, Canada, New Zealand, the U.K. or the U.S.
- Indication
Used primarily in the treatment of major depressive disorder and anxiety . It is currently being studied for fibromyalgia pain treatment .
- Associated Conditions
- Major Depressive Disorder (MDD)
- Associated Therapies
- -
Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Tianeptine in the Treatment of Covid Fog Symptoms in Patients After COVID-19.
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Military Institute od Medicine National Research Institute
- Target Recruit Count
- 140
- Registration Number
- NCT06012552
- Locations
- 🇵🇱
Anna Klimkiewicz, Warsaw, Poland
The Efficacy of Tianeptine Versus Pregabalin on Acute and Chronic Post Mastectomy Pain After Breast Cancer Surgery.
- Conditions
- Post-mastectomy Pain Syndrome
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- National Cancer Institute, Egypt
- Target Recruit Count
- 90
- Registration Number
- NCT05935059
- Locations
- 🇪🇬
National Cancer Institute Cairo University, Cairo, Egypt
Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea
- Conditions
- Major Depression
- Interventions
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 370212
- Registration Number
- NCT04446039
- Locations
- 🇰🇷
Pfizer, Seoul, Korea, Republic of
Tianeptine for Treatment Resistant Depression
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 75
- Registration Number
- NCT04249596
- Locations
- 🇺🇸
Mood and Anxiety Disorders Program at the Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Stanford Depression Research Clinic at Stanford University School of Medicine, Stanford, California, United States
🇺🇸New York State Psychiatric Institute, New York, New York, United States
Brain Response to Serotonergic Medications in ASD
- Conditions
- Autism Spectrum Disorder
- Interventions
- First Posted Date
- 2019-10-30
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- King's College London
- Target Recruit Count
- 100
- Registration Number
- NCT04145076
- Locations
- 🇬🇧
King's College London, London, United Kingdom
Comparison of Tianeptine Versus Escitalopram Patients Major Depressive Disorder
- First Posted Date
- 2011-03-07
- Last Posted Date
- 2013-01-25
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 164
- Registration Number
- NCT01309776
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Inje University Paik Hospital, Goyang, Korea, Republic of
Efficacy of Adjunctive Tianeptine in the Treatment of Bipolar Depression
- First Posted Date
- 2009-04-10
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 13
- Registration Number
- NCT00879372
- Locations
- 🇧🇷
Hospital de Clinicas de Porto Alegre, Porto Alegre, RS, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.